Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab-Reference-Cited by-同舟云学术

Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab

Published:2005-08 Issue:3 Volume:6 Page:240-246
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Mass Robert D.,Press Michael F.,Anderson Steven,Cobleigh Melody A.,Vogel Charles L.,Dybdal Noël,Leiberman Grazyna,Slamon Dennis J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

2. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization;Kallioniemi;Proc Natl Acad Sci U S A,1992

3. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization;Pauletti;Oncogene,1996

4. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

5. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens;Press;J Clin Oncol,2002

Cited by 304 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden;Medical Decision Making;2024-09-12

2. Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2–Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry;JCO Oncology Advances;2024-09

3. Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study;Breast Cancer Research and Treatment;2024-08-22

4. Artificial intelligence for assisted HER2 immunohistochemistry evaluation of breast cancer: A systematic review and meta-analysis;Pathology - Research and Practice;2024-08

5. Expanding the treatment options for HER2-low metastatic breast cancer: Experience with trastuzumab deruxtecan in aggressive luminal HER2-low breast cancer;Meditsinskiy sovet = Medical Council;2024-07-24